Spero Therapeutics Inc SPRO

NAS: SPRO | ISIN: US84833T1034   14/11/2024
1,250 USD (-4,58%)
(-4,58%)   14/11/2024

11 oktober 2023 · SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors · Persbericht

22 september 2022 · GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr · Persbericht

21 juli 2022 · Pomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers - SPRO · Persbericht

21 juli 2022 · SPRO Investors Have Opportunity to Lead Spero Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

17 juni 2022 · SPRO Investors Have Opportunity to Lead Spero Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

1 juni 2022 · Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm · Persbericht

5 juli 2021 · Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories · Persbericht

11 maart 2021 · Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update · Persbericht

3 maart 2021 · Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021 · Persbericht

5 februari 2021 · Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial · Persbericht

29 januari 2021 · Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Mijn selecties